Personalized Medicine – News and Features

Discover how epiproteomics unlocks new biomarkers and drives breakthroughs in diagnostics and drug development.

Researchers have uncovered multiple new genes and genetic pathways that could lead to repurposing hundreds of existing drugs for osteoarthritis, the most common form of arthritis.

Today, our approach to irAE management is predominantly reactive. Clinical guidelines, while increasingly robust, are designed to detect and treat toxicity after it arises. This framework, though necessary, falls short of what is now possible.

Researchers have shown comprehensively that a combination of two lipoprotein markers, measured in a simple blood test, can give more accurate information about individual risk of heart disease than the current blood cholesterol test.

Dr. Paulina Bernal’s research on volumetric bioprinting has led to the development of faster, more efficient tissue models. This technique holds promise for regenerative medicine and personalized treatments.

Mapping a tumor's cellular neighborhood in three dimensions could identify potential targets for personalized cancer therapy.

Researchers have made a major breakthrough with the potential to turn intravenous drugs into oral treatments for diseases like brain cancer and Alzheimer’s disease.

By studying mutations in a gene called neurexin-1, which is highly associated with both schizophrenia and autism, researchers have discovered that different types of mutations in the gene require different treatments.

Stanford Medicine researchers have created a liquid biopsy test capable of detecting cancers, molecular mechanisms of resistance to treatment and tissue injury.

Conducting a meta-analysis of genetic databases involving nearly 2 million people including nearly half a million patients with osteoarthritis, researchers found 962 genetic markers associated with the condition.